New horizons for therapeutic nuclear medicine in 1981
Conference
·
· J. Nucl. Med.; (United States)
OSTI ID:6482844
The therapeutic approach of internally administered radiopharmaceuticals offers the potential to outmode the present approaches of conventional radiation therapy and chemotherapy because of three characteristics: (1) the therapeutic use of radiopharmaceuticals may deliver as much as orders of magnitude larger rad doses than conventional radiation therapy to target tissues, selectively irradiating these tissues internally in one radiation dose; (2) the therapeutic use of radiopharmaceuticals is followed by a lower incidence of leukemia and other cancers; (3) the treatment is comparatively noninvasive and nontraumatic. It is now possible to make this rather strong statement with fairly firm conviction because Na/sup 131/I has been used since 1946 to treat almost a million patients for hyperthyroidism (a) and in approximately 5000 patients for well-differentiated thyroid cancer (b); NaH/sub 2/PO/sub 4/ (P-32) has been used for 35 years to treat approximately 25,000 patients with polycythemia vera.
- Research Organization:
- Univ. of Michigan, Ann Arbor
- OSTI ID:
- 6482844
- Conference Information:
- Journal Name: J. Nucl. Med.; (United States) Journal Volume: 22:6
- Country of Publication:
- United States
- Language:
- English
Similar Records
New horizons for therapeutic nuclear medicine in 1981
Horizons in radionuclide therapy: 1985 update
Association between systemically administered radioisotopes and subsequent malignant disease
Journal Article
·
Mon Jun 01 00:00:00 EDT 1981
· J. Nucl. Med.; (United States)
·
OSTI ID:5638150
Horizons in radionuclide therapy: 1985 update
Journal Article
·
Sun Mar 31 23:00:00 EST 1985
· J. Nucl. Med.; (United States)
·
OSTI ID:5708455
Association between systemically administered radioisotopes and subsequent malignant disease
Conference
·
Sat Jan 31 23:00:00 EST 1976
· Cancer, Suppl., v. 37, no. 2, pp. 1097-1101
·
OSTI ID:4031372
Related Subjects
550604 -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
560161* -- Radionuclide Effects
Kinetics
& Toxicology-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKALI METAL COMPOUNDS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
ENDOCRINE DISEASES
ENDOCRINE GLANDS
GLANDS
HALIDES
HALOGEN COMPOUNDS
HEMIC DISEASES
HYPERTHYROIDISM
INORGANIC PHOSPHORS
INTERMEDIATE MASS NUCLEI
IODIDES
IODINE 131
IODINE COMPOUNDS
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
LEUKEMIA
LIGHT NUCLEI
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
ORGANS
PATIENTS
PHOSPHORS
PHOSPHORUS 32
PHOSPHORUS ISOTOPES
RADIOINDUCTION
RADIOISOTOPES
RADIOLOGY
RADIOPHARMACEUTICALS
RADIOTHERAPY
SIDE EFFECTS
SODIUM COMPOUNDS
SODIUM IODIDES
THERAPY
THYROID
560161* -- Radionuclide Effects
Kinetics
& Toxicology-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ALKALI METAL COMPOUNDS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DISEASES
DRUGS
ENDOCRINE DISEASES
ENDOCRINE GLANDS
GLANDS
HALIDES
HALOGEN COMPOUNDS
HEMIC DISEASES
HYPERTHYROIDISM
INORGANIC PHOSPHORS
INTERMEDIATE MASS NUCLEI
IODIDES
IODINE 131
IODINE COMPOUNDS
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
LEUKEMIA
LIGHT NUCLEI
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
ORGANS
PATIENTS
PHOSPHORS
PHOSPHORUS 32
PHOSPHORUS ISOTOPES
RADIOINDUCTION
RADIOISOTOPES
RADIOLOGY
RADIOPHARMACEUTICALS
RADIOTHERAPY
SIDE EFFECTS
SODIUM COMPOUNDS
SODIUM IODIDES
THERAPY
THYROID